Texas Yale Capital Corp’s PDL BioPharma, Inc. PDLI Stock Holding History

Texas Yale Capital Corp’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-38,150	Closed	-$369K	–	442
2014 Q2	$369K	Hold	38,150	–	–	0.05%	293
2014 Q1	$317K	Hold	38,150	–	–	0.04%	298
2013 Q4	$322K	Hold	38,150	–	–	0.05%	237
2013 Q3	$304K	Hold	38,150	–	–	0.05%	241
2013 Q2	$295K	Buy	+38,150	New	+$297K	0.05%	224

Other funds holding PDLI

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Texas Yale Capital Corp's PDLI Position: Q3 2014 in Review

Texas Yale Capital Corp sold out of PDL BioPharma, Inc. (PDLI) in Q3 2014, closing a stake of 38,150 shares — an estimated $369K sold.

Texas Yale Capital Corp first reported a position in PDLI in Q2 2013 and held it in 5 quarters. The position peaked at $369K in Q2 2014. 231 funds tracked by Wall St. Rank hold PDLI as of Q3 2014.

Texas Yale Capital Corp reported no remaining PDL BioPharma, Inc. position as of Q3 2014 after selling out during the quarter.
Texas Yale Capital Corp sold 38,150 PDL BioPharma, Inc. shares in Q3 2014, an estimated $369K.
Texas Yale Capital Corp first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 5 quarters.
Texas Yale Capital Corp's PDL BioPharma, Inc. position peaked at $369K in Q2 2014.
231 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2014.

Based on Texas Yale Capital Corp's 13F filing for Q3 2014, filed 13 Nov 2014.